---
layout: default
title: Sugammadex
parent: AI Predictions (L5)
nav_order: 557
evidence_level: L5
indication_count: 10
---

# Sugammadex
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sugammadex: From Neuromuscular Blockade Reversal to Breast Fibrocystic Disease

## One-Sentence Summary

Sugammadex is a cyclodextrin-based binding agent used during anesthesia to reverse rocuronium/vecuronium-induced neuromuscular blockade.
The TxGNN model predicts it may be effective for **Breast Fibrocystic Disease**,
but currently **0 clinical trials** and **0 publications** support this direction, and the evidence pack's own mechanistic review found no known biological link between the two.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Reversal of rocuronium/vecuronium-induced neuromuscular blockade (derived from evidence pack rationale text; formal regulatory indication text unavailable — see Data Gaps below) |
| Predicted New Indication | Breast Fibrocystic Disease |
| TxGNN Prediction Score | 98.49% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on information contained in this evidence pack, Sugammadex is a modified cyclodextrin whose only established pharmacological action is to selectively encapsulate the steroidal neuromuscular blocking agents rocuronium and vecuronium, thereby reversing anesthesia-induced muscle paralysis. This is a narrow molecular-trapping mechanism with no known involvement of hormone receptors, growth factor signaling, or other pathways relevant to breast tissue.

Breast fibrocystic disease is a benign, estrogen/progesterone-sensitive proliferative condition of breast epithelium. There is no structural, receptor-level, or pathway-level overlap between this condition and sugammadex's mechanism of action. The evidence pack's own mechanistic assessment for this specific prediction states explicitly that no known receptor or pathway link exists, and no clinical trials or literature have been found linking the two.

Given the absence of any supporting mechanistic, preclinical, or clinical evidence, this ranking appears to be driven purely by knowledge-graph embedding similarity rather than any biologically plausible rationale. It should be treated as a hypothesis-generation signal only, consistent with its L5 evidence level and Hold recommendation.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## EU Market Information

No EU marketing authorizations are recorded for Sugammadex in this dataset (market status: Not Marketed, total licenses: 0).

## Safety Considerations

Please refer to the SmPC for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No clinical trials or peer-reviewed literature currently support efficacy of sugammadex in breast fibrocystic disease, and the evidence pack's own mechanistic review found no known receptor or pathway connection between the drug and the disease. The prediction rests entirely on a TxGNN embedding score (L5), with no experimental validation.

**To proceed, the following is needed:**
- Formal mechanism-of-action documentation from DrugBank (currently marked as a High-severity data gap, DG002)
- TFDA/EMA label warnings, contraindications, and DDI data (currently a Blocking data gap, DG001, preventing entry into S1 safety screening)
- Preclinical or in vitro studies establishing a plausible biological link between sugammadex and breast epithelial proliferation before any further evaluation
- If exploratory value is still of interest, note that among the other candidate indications in this evidence pack, only "thrombotic disease" (rank 6) reached L4/S1 status, based on two papers (PMID 28714298, 22577926) reporting a coagulation *safety* signal in ROTEM studies — not a therapeutic efficacy signal — and would warrant separate, more cautious evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

